News Conference News TCT 2025 LIFE-BTK: 3-Year Data Keep Dissolving Scaffold’s Durability Hopes Alive in CLTI L.A. McKeown October 27, 2025
News Opinion Editor's Corner TCT 2025 What’s Going to Be Hot at TCT 2025 Michael O'Riordan October 09, 2025
News Opinion Editor's Corner ACC 2025 What’s Going to Be Hot at ACC 2025? Michael O'Riordan March 26, 2025
News Daily News Take Heed of Sex Differences in Peripheral Vascular Disease: AHA Michael O'Riordan March 13, 2025
News Conference News ISC 2025 Lower Diagnostic Success With Transradial Cerebral Angiography Todd Neale February 07, 2025
News Conference News VIVA 2024 DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years L.A. McKeown November 11, 2024
News Conference News VIVA 2024 Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK L.A. McKeown November 05, 2024
Presentation TCT 2024 TCT 318: Correlation Between Coronary Artery Disease Severity and Carotid Stenosis Characteristics in Candidates for Carotid Revascularization Presenter: Hiroyuki Nakajima October 29, 2024
Presentation TCT 2024 TCT 695: Trends and Outcomes of Lower Limb Amputation in Patients With Coronary Artery Disease: Insight From Nationwide Inpatient Sample Presenter: Abdul Rasheed Bahar October 28, 2024
News Conference News ESC 2024 New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document Caitlin E. Cox September 10, 2024
News Opinion CV Team Dispatch September 2024 Dispatch for the CV Team L.A. McKeown September 01, 2024
News Daily News Scientific Statement Reviews Current Antithrombotic Options in PAD L.A. McKeown August 26, 2024
News Daily News New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients L.A. McKeown August 19, 2024
News Daily News Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years Yael L. Maxwell June 26, 2024
News Conference News ACC 2024 IVUS Benefits Patients Receiving DCBs for Fem-Pop Disease Caitlin E. Cox April 10, 2024
News Daily News Mechanism’s Mojo: ‘Obvious’ CV Therapies More Likely to Be Seen as Effective Michael O'Riordan February 23, 2024